Cargando…

A phase 1 study of tazarotene in adults with advanced cancer

Tazarotene is an acetylenic retinoid which is metabolised to tazarotenic acid and which binds selectively to the retinoid receptors RARβ and RARγ. The safety, toxicity and pharmacokinetics of oral tazarotene were determined over 12 weeks of treatment in 34 patients with advanced cancer. Commonly see...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jones, P H, Burnett, R D, Fainaru, I, Nadolny, P, Walker, P, Yu, Z, Tang-Liu, D, Ganesan, T S, Talbot, D C, Harris, A L, Rustin, G J S
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2003
Materias:	Clinical
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2394470/ https://www.ncbi.nlm.nih.gov/pubmed/12942109 http://dx.doi.org/10.1038/sj.bjc.6601169

Ejemplares similares

Tazarotene as alternative topical treatment for onychomycosis
por: Campione, Elena, et al.
Publicado: (2015)

Phase II trial of the antiangiogenic agent IM862 in metastatic renal cell carcinoma
por: Deplanque, G, et al.
Publicado: (2004)

A review of tazarotene in the treatment of photodamaged skin
por: Ogden, Stephanie, et al.
Publicado: (2008)

Use of tazarotene foam for the treatment of acne vulgaris
por: Gregoriou, Stamatis, et al.
Publicado: (2014)

Safety and efficacy of tazarotene foam for the treatment of acne vulgaris
por: Epstein, Erica L, et al.
Publicado: (2013)

A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer
por: Rustin, G J, et al.
Publicado: (2010)

Combination antiangiogenesis therapy with marimastat, captopril and fragmin in patients with advanced cancer
por: Jones, P H, et al.
Publicado: (2004)

Comparison of prognostic factors in patients in phase I trials of cytotoxic drugs vs new noncytotoxic agents
por: Han, C, et al.
Publicado: (2003)

A phase I (tumour site-specific) study of carboplatin and temozolomide in patients with advanced melanoma
por: Strauss, S J, et al.
Publicado: (2003)

Successful treatment of median canaliform nail dystrophy with topical tazarotene foam
por: Quan, Eugenie Y., et al.
Publicado: (2022)

Impact of Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045% in the Management of Plaque Psoriasis in Adults
por: Reddy, Vidhatha, et al.
Publicado: (2020)

Tazarotene gel with narrow-band UVB phototherapy: a synergistic combination in psoriasis
por: Dayal, Surabhi, et al.
Publicado: (2018)

Photostability Testing of a Third-Generation Retinoid—Tazarotene in the Presence of UV Absorbers
por: Kryczyk-Poprawa, Agata, et al.
Publicado: (2020)

A Case of Pincer Nail Successfully Treated with Tazarotene 0.1% Gel
por: Vollono, Laura, et al.
Publicado: (2020)

Drug screening identifies tazarotene and bexarotene as therapeutic agents in multiple sulfatase deficiency
por: Schlotawa, Lars, et al.
Publicado: (2023)

A phase I and pharmacological study of the matrix metalloproteinase inhibitor BB-3644 in patients with solid tumours
por: Wall, L, et al.
Publicado: (2004)

BOWENOID PAPULOSIS OF THE GENITALIA SUCCESSFULLY TREATED WITH TOPICAL TAZAROTENE: A REPORT OF TWO CASES
por: Shastry, Veeranna, et al.
Publicado: (2009)

A phase II study of sequential carboplatin, paclitaxel and topotecan in patients with previously untreated advanced ovarian cancer
por: Guppy, A E, et al.
Publicado: (2004)

Tazarotene-Induced Gene 1 Enhanced Cervical Cell Autophagy through Transmembrane Protein 192
por: Shyu, Rong-Yaun, et al.
Publicado: (2016)

Tazarotene-Induced Gene 1 Interacts with DNAJC8 and Regulates Glycolysis in Cervical Cancer Cells
por: Wang, Chun-Hua, et al.
Publicado: (2018)

Randomised, phase II trial comparing oral capecitabine (Xeloda®) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines
por: Talbot, D C, et al.
Publicado: (2002)

A multicentre phase II trial of bryostatin-1 in patients with advanced renal cancer
por: Madhusudan, S, et al.
Publicado: (2003)

Fixed-Combination Halobetasol Propionate and Tazarotene in the Treatment of Psoriasis: Narrative Review of Mechanisms of Action and Therapeutic Benefits
por: Lebwohl, Mark G., et al.
Publicado: (2021)

Microsponge based gel as a simple and valuable strategy for formulating and releasing Tazarotene in a controlled manner
por: Khattab, Alaa, et al.
Publicado: (2022)

Tackling acne vulgaris by fabrication of tazarotene-loaded essential oil-based microemulsion: In vitro and in vivo evaluation
por: Badawi, Noha M., et al.
Publicado: (2023)

EVALUATION OF TOPICAL 0.1% TAZAROTENE CREAM IN THE TREATMENT OF PALMOPLANTAR PSORIASIS: AN OBSERVER-BLINDED RANDOMIZED CONTROLLED STUDY
por: Mehta, Bijal H, et al.
Publicado: (2011)

Tazarotene-Induced Gene 3 May Affect Inflammatory Angiogenesis in Psoriasis by Downregulating Placental Growth Factor Expression
por: Jeon, Su-Young, et al.
Publicado: (2014)

GelMA/PEGDA microneedles patch loaded with HUVECs-derived exosomes and Tazarotene promote diabetic wound healing
por: Yuan, Meng, et al.
Publicado: (2022)

Phase II trials of rhizoxin in advanced ovarian, colorectal and renal cancer.
por: Kerr, D. J., et al.
Publicado: (1995)

Phase II study to evaluate combining gemcitabine with flutamide in advanced pancreatic cancer patients
por: Corrie, P, et al.
Publicado: (2002)

Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies
por: Eisen, T, et al.
Publicado: (2011)

Tazarotene-induced gene 1 inhibits prostaglandin E2-stimulated HCT116 colon cancer cell growth
por: Tsai, Fu-Ming, et al.
Publicado: (2011)

5,6-Dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study
por: Rustin, G J S, et al.
Publicado: (2003)

Sunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding study
por: Michaelson, M D, et al.
Publicado: (2013)

A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer
por: Hussain, S A, et al.
Publicado: (2004)

Phase II trial of UFT in advanced colorectal and gastric cancer.
por: Malik, S. T., et al.
Publicado: (1990)

Phase II study of capecitabine and mitomycin C as first-line treatment in patients with advanced colorectal cancer
por: Rao, S, et al.
Publicado: (2004)

A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients
por: Bleumer, I, et al.
Publicado: (2004)

A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers
por: Vasey, P A, et al.
Publicado: (2008)

A phase II study of bryostatin 1 in metastatic malignant melanoma.
por: Propper, D. J., et al.
Publicado: (1998)

Cannot write session to /tmp/vufind_sessions/sess_kn6j8k7pdvopkas0rapf0cg93f